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Abstract
Objectives: Myostatin, a member of the transforming growth factor-beta (TGF-β) family, plays a key role in skeletal muscle myogenesis by
limiting hyperplastic and hypertrophic muscle growth. In cardiac muscle, myostatin has been shown to limit agonist-induced cardiac
hypertrophic growth. However, its role in cardiac hyperplastic growth remains undetermined. The aim of this study was to characterise the
expression of myostatin in developing myocardium, determine its effect on cardiomyocyte proliferation, and explore the signalling
mechanisms affected by myostatin in dividing cardiomyocytes.
Methods: We used quantitative PCR and Western blotting to study the expression of myostatin in cardiomyocytes isolated from rat
myocardium at different developmental ages. We determined the effect of recombinant myostatin on proliferation and cell viability in
dividing cardiomyocytes in culture. We analysed myostatin's effect on cardiomyocyte cell cycle progression by flow cytometry and used
Western blotting to explore the signalling mechanisms involved.
Results: Myostatin is expressed differentially in cardiomyocytes during cardiac development such that increasing expression correlated with
a low cardiomyocyte proliferation index. Proliferating foetal cardiomyocytes, from embryos at 18 days of gestation, expressed low levels of
myostatin mRNA and protein, whereas isolated cardiomyocytes from postnatal day 10 hearts, wherein the majority of cardiomyocytes have
lost their ability to proliferate, displayed a 6-fold increase in myostatin expression. Our in vitro studies demonstrated that myostatin inhibited
proliferation of dividing foetal and neonatal cardiomyocytes. Flow cytometric analysis showed that this inhibition occurs mainly via a block
in the G1-S phase transition of the cardiomyocyte cell cycle. Western blot analysis showed that part of the mechanism underpinning the
inhibition of cardiomyocyte proliferation by myostatin involves phosphorylation of SMAD2 and altered expressions of the cell cycle proteins
p21 and CDK2.
Conclusions: We conclude that myostatin is an inhibitor of cardiomyocyte proliferation with the potential to limit cardiomyocyte
hyperplastic growth by altering cardiac cell cycle progression.
© 2007 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
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1. Introduction
The proliferative capacity of mammalian foetal cardio-
myocytes diminishes dramatically during early neonatal
development [1–3]. From this point onward, most of the
adaptive growth needed to accommodate increased cardiac
workload is accomplished by myocyte hypertrophy [3]. The
inability of mature cardiomyocytes to proliferate, but instead
grow by hypertrophy, has serious consequences for patients
who suffer from heart failure post-infarct [4] or genetic
cardiomyopathies that lead to progressive fibro fatty
replacement of cardiac tissue, such as arrythmogenic right
ventricular cardiomyopathy [5]. Identifying the key regula-
tors of cardiomyocyte proliferation and understanding the
Cardiovascular Research 74 (2007) 304–312
www.elsevier.com/locate/cardiores
⁎ Corresponding author. Tel.: +44 118 378 6565; fax: +44 118 378 6562.
E-mail address: g.brooks@reading.ac.uk (G. Brooks).
1 These authors contributed equally to this study.
0008-6363/$ - see front matter © 2007 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
doi:10.1016/j.cardiores.2007.02.023
b
y
 
g
u
e
s
t
 
o
n
 
O
c
t
o
b
e
r
 
3
1
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 molecular mechanisms involved in limiting the ability of
cardiomyocytes to divide, therefore, is crucial if we are to
develop new therapies to treat such heart diseases.
The loss intheability ofdifferentiatedadult cardiomyocytes
to divide has been the focus of interest for a number of
researchers [6,7]. During cardiac development, it has been
observed that changes in the proliferative capacity of
cardiomyocytes coincide with a biochemical block in cardiac
cell cycle progression leading to terminal differentiation [2,8].
In an attempt to stimulate cardiomyocytes to undergo cell
division and repair damaged myocardial tissue, considerable
efforts have been focussed on identifying putative regulators
andmolecularmechanismsthataltertheexpressionandactivity
of cell cycle molecules involved in myocyte proliferation [7].
Myostatin, also known as Growth and Differentiation
Factor-8, is a member of the TGF-beta (TGF-β) super family
of secreted proteins and a potent inhibitor of skeletal muscle
mass [9]. Studies in cattle and mice [9,10] have demonstrated
that absence or impaired functioning of myostatin results in
hyperplastic and/or hypertrophic growth of skeletal muscle,
whilst increased levelsofmyostatinintheserum andmuscles
of patients with cachexia and HIV infection is linked to the
musclewastingdiseaseseeninthesepatients[11].Recently,a
naturally occurring myostatin mutation has been identified in
humans such that a male patient showed increased muscle
mass compared to other boys of his age [12]. Together, these
studies demonstrate that myostatin affects both hyperplastic
and hypertrophic skeletal muscle growth. Myostatin mRNA
and protein are also expressed in cardiac muscle [13] and it
has been shown that myostatin affects adaptive hypertrophic
growth in serum-starved neonatal rat cardiomyocytes [14].
However, the effect of myostatin on cardiomyocyte prolif-
eration remains undetermined.
To study the role of myostatin in cardiac muscle prolifera-
tion, we firstly determined its expression in foetal cardiomyo-
cytes with high proliferation index, in neonatal cardiomyocytes
with lower proliferation index that decreases with age and in
adult rat hearts wherein the majority of cardiomyocyte have lost
their ability to divide [1–3]. We observed that myostatin is
expressed developmentally. Our in vitro studies demonstrated
that myostatin limited cardiomyocyte proliferation and caused
cell cycle arrest. Myostatin also induced SMAD2 phosphory-
lation and altered the expression of cell cycle proteins
critical for S-phase entry in proliferating cardiomyocytes.
These findings highlight the potential of myostatin to limit
cardiomyocyte proliferation and suggest that this inhibition
involves SMAD2 signalling and cell cycle regulation.
2. Materials and methods
2.1. Animals
Wistar rats were obtained from Charles River Laborato-
ries, UK. All animal experiments complied with the United
Kingdom Animal Scientific Procedures Act 1986 as well as
with the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996) and were approved by
the ethical committee of the University of Reading, UK.
2.2. Recombinant myostatin
Bacterially-expressed recombinant myostatin was a kind
gift from Professor Ravi Kambadur, University of Waikato,
New Zealand [13]. Recombinant myostatin, purified from
mouse myeloma cell line, NS0, was purchased from R&D
Systems. Variations in the relative amounts of correctly
folded bioactive protein in purified preparations of the
recombinant protein have been described for members of the
TGF-β [19] including myostatin [20]. Hence, concentrations
of recombinant myostatin from different sources/lots that
resulted in greater than 45% inhibition of proliferation in P2
rat cardiomyocytes after 72 h of treatment were empirically
determined (see Table 1) and used in this study.
2.3. Isolation of primary cardiomyocyte
Cardiomyocytes from, embryonic age 18 (E18), postnatal
ages 0, 2, 5 and 10 (P0, P2, P5 and P10, respectively) rat
ventricles were obtained by serial enzymatic digestions. Adult
(Ad)cardiomyocyteswerepreparedbyLangendorffperfusion
[21]. Isolated cardiomyocytes preparations were N95% pure
as revealed by staining with cardiac-specific sarcomeric actin
(Abcam, UK) antibody.
2.4. Cardiomyocyte culture and growth inhibition studies
Isolated E18 and P0 rat cardiomyocytes were seeded at a
density of 2×10
5/well in 6 well dishes and grown in myocyte
medium (DMEM/M199 (4:1) containing 5% foetal bovine
serum(FBS)for24h.Recombinantmyostatinwasthenadded
to appropriate cultures. At various time points thereafter,
myostatin treated and untreated control cardiomyocytes were
harvested by trypsinisation for analysis. Viable cells identified
bytrypanblueexclusionwerecountedusingahaemocytometer.
Table 1
Effect of recombinant myostatin on P2 cardiomyocyte proliferation
Myostatin concentration Mean cell no.±SD (n=3) % Growth
Recombinant myostatin (E. coli)
0 μg/ml 210,552±1661 100
1 μg/ml 174,173±4475⁎ 82.7
5 μg/ml 88,635±805⁎ 42.1
Recombinant myostatin (mouse myeloma, lot EZ11612A, R&D)
0 ng/ml 206,667±14,434 100
250 ng/ml 155,000±5000⁎ 75
500 ng/ml 110,000±5000⁎ 53.2
Proliferating cardiomyocytes were treated with indicated concentrations of
myostatin for 72 h. Viable cells were identified by trypan blue exclusion and
counted using a haemocytometer. ⁎ indicates significant difference to
untreated control cultures.
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 2.5. Measurement of cell death
Propidium iodide (PI) uptake was used as a marker of
dying cells that have lost their cell-membrane integrity to
determine whether myostatin induced cell death in prolifer-
ating cardiomyocytes. Briefly, E18 cardiomyocytes cultured
for 72 h with or without myostatin were harvested. Adherent
and non-adherent cells from respective cultures were pooled,
washed with PBS and incubated in PI buffer(PBS containing
3% FBS and PI; 20 μg/ml) at 4 °C for 20 min. Sorting of PI
positive cells was performed using a FACSCalibur flow
cytometer (BD Biosciences). Loss of plasma membrane per-
meability was quantified as the percentage of cells positively
stained by PI.
2.6. Fluorescence activated cell sorting (FACS) analysis
Two-colour flow cytometric analysis was performed on
ethanol-fixed cardiomyocytes. Briefly, foetal cardiomyo-
cytes seeded at a density of 1×10
6 cells/10 cm
2 dish were
grown in 5% FBS myocyte media with or without myostatin
for 48 h. Cells then were pulse-labelled with 10 μM bro-
modeoxyuridine (BrdU) for 30 min at 37 °C and prepared for
FACS analysis as described [21]. Labelled nuclei were
stained with anti-BrdU antibody and PI and analysed using a
FACS Calibur flow cytometer and the CellQuest software
(BD Biosciences). Flow cytometric measurements were
performed on samples containing 10,000–30,000 cells. Car-
diomyocytes were gated into the respective cell cycle phases
(G0/G1, S and G2/M) as described [21].
2.7. Protein synthesis analysis
The effect of myostatin on protein synthesis in cultured
cardiomyocytes was evaluated using [
14C]-phenylalanine
incorporation as an index. For proliferating cardiomyocytes,
E18 myocytes were cultured in 5% FBS myocyte media with
or without myostatin for 24 h. [
14C]-phenylalanine (0.1 μCi/
ml) was then added to each culture and allowed to grow for a
further 24 h. For non-dividing cardiomyocytes, P2 myocytes
cultured in 5% FBS myocyte media for 24 h were serum
starved for 48 h. Phenylephrine (PE) (100 μM) with or
without 500 ng/ml myostatin (R&D) and 0.1 μCi/ml [
14C]-
phenylalanine was then added to respective cultures and
grown for a further 24 h. Cells were washed with PBS and
ice-cold trichloroacetic acid (10%) and the precipitated
proteins solubilized in 0.1 N NaOH and 0.01% SDS at 37 °C.
Samples were mixed with scintillation fluid (3 ml) and
quantified using a liquid scintillation counter.
2.8. Western blotting
To assess the expression of myostatin protein in
cardiomyocytes isolated from foetal (E18), neonatal (P2,
P5 and P10) and adult rat hearts, protein extracts prepared as
described previously [21] were analysed by Western blotting
by using the anti-myostatin rabbit polyclonal antibody
previously described [13]. For analysis of phospho protein
and cell cycle proteins, myostatin treated and control E18
cardiomyocytes from triplicate experiments were washed
with ice cold PBS and scraped directly in protein lysis buffer.
Pooled protein extracts from each treatment group were
Fig. 1. Developmental expression of myostatin in isolated rat cardiomyo-
cytes. Myostatin (a) mRNA and (b) protein levels are expressed
differentially in foetal (E 18), neonatal (P2, P5 and P10) and adult (Ad)
rat cardiomyocytes as determined by qPCR and Western blot analysis,
respectively. For qPCR analysis, cardiomyocytes isolated from hearts of
pups (n=4–6 separate litters) were used to generate total RNA analysed for
each data point. For protein analysis, 20 μg of total protein isolated from
foetal (E 18), neonatal (P2, P5 and P10) and adult (Ad) rat cardiomyocytes
were subjected to Western blot analysis and probed with a rabbit anti-
myostatin polyclonal antibody. The position of myostatin precursor protein
and active C-terminal myostatin band is indicated as previously described
[13]. GAPDH was used as loading control. (c) Relative abundance of the
processed, active form of myostatin as determined by densitometric analysis
of at least 4 independent experiments. ⁎ indicates pb0.05 relative to
myostatin levels in E18 cardiomyocytes.
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 analysed by Western blotting using antibodies against
phospho-SMAD2 (Chemicon), SMAD2/3 (Upstate biotech-
nology), p21 and CDK2 (Santa Cruz Biotechnology Ltd).
GAPDH (Abcam) was used to correct for protein loading.
Relative protein abundance was determined by densitometric
analysis, in which signal intensities within the linear range
on X-ray film were converted to numerical values using
Quantity One® densitometric analysis software (Bio-Rad).
2.9. Quantitative RT-PCR
Real-time quantitative RT-PCR (qPCR) was used to
evaluate myostatin mRNA expression in E18, P2, P5, P10
and adult rat cardiomyocytes, as well as p21 mRNA
expression in E18 cardiomyocytes following myostatin
treatment. RNA isolation and cDNA synthesis was per-
formed as previously described [22]. Real-time quantitative
PCR analysis was performed using ABsolute™ QPCR ROX
mix (ABgene) and a GeneAmp® 5700 sequence detector
(Applied Biosystems). Myostatin cDNAwas amplified using
forward primer, 5′-CGCTACCACGGAAACAATCATT-3′,
and reverse primer, 5′-GCTTTCCATCCGCTTGCAT-3′ and
the amplified product detected using a myostatin-specific
Taqman® probe, 5′-(FAM)-CCATGCCTACCGAGTCT-
GACTTTC-(TAMRA)-3′. p21 cDNA was amplified using
forward primer, 5′-AGAGCCACAGGCACCATGTC-3′,
and reverse primer, 5′-CGAACAGACGACGGCATACTT-
3′ and the amplified product detected using a p21-specific
Taqman® probe, 5′-(FAM)-ATCCTGGTGATGTCC-
GACCTGTTCCAC-(TAMRA)-3′. Real-time PCR analysis
was normalized using the rodent GAPDH control reagent kit
(Applied Biosystems).
2.10. Statistical analysis
At least three independent experiments were performed
for all quantitation analysis. Student's t-test was used for
paired data analysis and for multiple data analysis one-way
analysis of variance followed by Bonferroni t-test was used.
Significance was accepted at pb0.05.
3. Results
3.1. Myostatin is expressed developmentally in cardiomyocytes
We and others have reported previously that there is a
greater percentage of proliferating cardiomyocytes in E18
rodent hearts compared to P2 hearts and that this decreases
withage[1–3].Wedeterminedwhethertherewasacorrelation
between these observedage-related changes incardiomyocyte
proliferative index and the temporal expression of myostatin,
by studying the expression of myostatin in cardiomyocytes
isolated from rat hearts at different developmental ages. Fig. 1
shows that myostatin is differentially expressed in rat
cardiomyocytesatvariousdevelopmentalstages.Accordingly,
E18 foetal cardiomyocytes display low levels of myostatin
Fig. 2. Myostatin mediated inhibition of rat cardiomyocyte proliferation. Myostatin treatment inhibits (a) foetal (E18) and (b) neonatal (P0) cardiomyocyte
proliferation. Cardiomyocytes were cultured in 5% FBS with or without 5 μg/ml recombinant E. coli overexpressed myostatin and harvested at the various time
points indicated. Viable cells were identified by trypan blue exclusion and counted using a haemocytometer. Day 0 time point represents the average number of
adherent cells/well (n=6) 24 h after plating. Data are mean values±SD of 4 independent experiments. (c) Inhibition of cardiomyocyte proliferation was not due
to loss of cell viability as determined by PI cell exclusion staining. (d) Inhibition by myostatin was reversible following myostatin release. In the release
experiments, cells were treated with 5 μg/ml of recombinant E. coli-expressed myostatin for 24 h then washed with PBS and cultured in 5% FBS myocyte
medium for a further 48 h. ⁎ pb0.05 for myostatin-treated compared with untreated control cultures.
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 expression compared to P2 cardiomyocytes which display
significantly higher level of myostatin mRNA (Fig. 1a). By
postnatal age 10, when the majority of cardiomyocytes have
lost their ability to proliferate [1–3], a 6-fold increase in
myostatin mRNA expression is observed compared to that in
E18cardiomyocytes(pb0.001).Westernblotanalysis(Fig.1b
and c) demonstrates that the levels of active myostatin protein
correlate strongly with myostatin mRNA levels, up to the age
ofP10.Thereafterinadultcardiomyocyte,a2-folddecreasein
the myostatin protein levels and a 15-fold decrease in mRNA
levels were observed. Since the majority of cardiomyocytes
lose their ability to proliferate during early postnatal
development [1–3], the increasing expression of myostatin
(particularly during the early postnatal period of cardiomyo-
cytegrowth)suggestsapotentialroleformyostatinduringthis
developmental growth phase.
3.2. Myostatin inhibits cardiomyocyte proliferation
In skeletal muscle, mature myostatin is a potent inhibitor
of skeletal muscle myoblast [23] and satellite cell [24] pro-
liferation. Therefore, we determined whether myostatin
would inhibit cardiomyocyte proliferation by adding recom-
binant myostatin to proliferating cultures. Fig. 2 shows that
the addition of recombinant myostatin to proliferating E18
(Fig. 2a) and P0 (Fig. 2b) rat cardiomyocyte cell cultures
significantly inhibited their proliferation. The inhibitory
effect of myostatin on cardiomyocyte proliferation was
evident 24 h after treatment and at all time points studied
thereafter. Quantitation of our results indicated that prolif-
eration of E18 and P0 cardiomyocytes was inhibited by 29%
and 21%, respectively after 24 h of myostatin treatment. The
effect of myostatin treatment was sustained since, at 72 h,
proliferation in E18 and P0 cultures was inhibited by 46%
and 58%, respectively relative to untreated controls. The
inhibition was not accompanied by increased cell death as
determined by PI cell exclusion staining (Fig. 2c).
It has been observed that myostatin acts in a novel manner
in that it blocks proliferation but that cells maintain their
ability to carry on dividing once myostatin is withdrawn
[25]. Thus, we investigated the ability of E18 cardiomyo-
cytes to resume proliferation once myostatin was removed.
Fig. 3. Myostatin alters the cell cycle profile of E18 cardiomyocytes. Representative cell cycle profiles of proliferating E18 cardiomyocytes cultured with or
without myostatin for 48 h. (a) BrdU treated cardiomyocytes were stained with anti-BrdU/FITC labelled secondary antibody and propidium iodide then analysed
by FACS. X-axis represents FL3-A (red flouresence) and Y-axis represents FL1-H (green fluorescence). (b) Graphical representation of the percentage of cells in
the G0/G1, S, or G2/M phases of the cell cycle following myostatin treatment for 48 h versus control. Data are mean values±SD from 3 independent
experiments. ⁎ indicates pb0.05.
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 E18 proliferating cardiomyocytes were cultured in the
myostatin-containing media for 24 h, this media was then
replaced with 5% FBS myocyte media and cardiomyocytes
cultured for a further 48 h. Inhibition of myocyte prolifera-
tion by myostatin was found to be reversible as demonstrated
by the reactivation of cardiomyocyte proliferation following
replacement of myostatin-containing media with 5% FBS
myocyte media (Fig. 2d).
3.3. Myostatin blocks G1 to S phase cell cycle progression
in cardiomyocytes
Flow cytometric analysis was performed to determine what
phaseofthemyocytecellcyclemyostatinaffected.Fig.3shows
that myostatin inhibited cardiomyocyte proliferation by block-
ingSphaseentryduringmyocytecellcycleprogression.Results
in Fig. 3b indicates that treatment of proliferating cardio-
myocytes withmyostatin for 48 h caused a 57–86% decreasein
the S phase population (pb0.05), and a concomitant increase of
7–14%, and 15–17% (though not statistically significant)
increase the G0/G1 and G2/M populations, respectively.
3.4. Myostatin treatment alters the expression of cell cycle
proteins necessary for G1 to S phase transition
In skeletal muscle myoblasts, myostatin treatment alters
the expression of cell cycle proteins, such as p21 and CDK2
[18,23]. We therefore examined whether myostatin treatment
affected the expression of cell cycle proteins critical for the
G1 to S-phase transition. Fig. 4a and b shows that in proli-
ferating E18 cardiomyocytes, myostatin treatment decreases
the expression of CDK2 protein significantly at 48 h.
However, by 72 h, as proliferating control cultures become
confluent and the rate of cell division ceases, a decreased
expression of CDK2 is also observed in untreated cultures
and at comparable levels to that observed in non-confluent
myostatin-treated cultures (Fig. 4b). Interestingly myostatin
mRNA is also upregulated as proliferating cardiomyocyte
cultures become confluent (data not shown). Myostatin
treatment also increased the mRNA (Fig. 4c) and protein
(Fig. 4d and e) expression of the cell cycle inhibitor p21 in
the proliferating E18 cultures significantly. A decreased (but
insignificant) expression of cyclin E protein was also
observed in some myostatin-treated cardiomyocyte cultures
(data not shown).
3.5. Effectsofmyostatinonproteinsynthesisincardiomyocytes
Recently, we demonstrated that myostatin inhibits PE-
induced protein synthesis rate per cell in serum-starved P2
neonatal cardiomyocytes thereby limiting agonist-induced
hypertrophy [14]. Thus, we compared the effect of myostatin
onproteinsynthesisinproliferatingfoetalcardiomyocytesand
serum-starved non-proliferating P2 neonatal cardiomyocytes
Fig. 4. Myostatin affects the expression of G1/S cell cycle proteins in E18 cardiomyocytes. Pooled protein extracts from triplicate experiments for each treatment
group were blotted onto PVDF membranes and probed with the antibodies indicated. GAPDH was used as loading control. (a) Representative Western blot
analysis of CDK2 expression shows that myostatin treatment decreases its expression in proliferating cardiomyocytes. (b) Densitometric analysis (n=5)
demonstrates that CDK2 expression is downregulated significantly in 48 h myostatin-treated cultures. (c) Myostatin-treatment increases the expression of p21
mRNA and (d) protein in E18 cardiomyocytes cultures. (e) Densitometric analysis (n=4) demonstrates that p21 protein expression is significantly upregulated
within 48 h of myostatin treatment.
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 by [
14C]-phenylalanine incorporation. Fig. 5a shows that total
proteinsynthesisinE18cardiomyocytesexposedtomyostatin
was significantly lower than that in untreated control cultures.
However,asshowninFig.5btheproteinsynthesisratepercell
(normally an indication of hypertrophic growth) was not
significantly different between myostatin treated and control
cultures.Thisisincontrasttotheeffectofmyostatinonserum-
starved P2 cardiomyocytes subjected to PE-induced hypertro-
phy (Fig. 5c) wherein a significant inhibition on the rate of
protein synthesis per cell and subsequently hypertrophic
growth[14]isevidentwithin24hofmyostatintreatment.This
suggeststhatthedecreaseintotalproteinsynthesisobservedin
myostatin-treated E18 cultures (Fig. 5a) reflects proliferation
inhibition and hence lower cardiomyocyte numbers relative to
untreated controls.
3.6. Acute myostatin treatment stimulates SMAD2 phos-
phorylation in E18 cardiomyocytes
Previous studies have demonstrated that members of the
TGF-β growth factor family of ligands including myostatin,
canelicitafunctionalresponsethroughtheclassicalSMAD2/3
signalling pathway [15–17]. We determined whether myos-
tatin activates a similar signalling pathway in proliferating
cardiomyocytes by Western blot analysis. Fig. 6 demonstrates
that myostatin induced SMAD2 phosphorylation in cardio-
myocytes within 30 min of treatment and that this phosphor-
ylation persisted (although at a reduced level) for up to 1 h.
SMAD2phosphorylation,however,droppedtobasallevelsby
3 h and no further increase in SMAD2 phosphorylation was
evident upto24h ofmyostatintreatment.Incontrast, Western
blot analysis using anti-SMAD2/3 specific antibody shows
that total SMAD2 protein remains unchanged in both
myostatin-treated and control cultures.
4. Discussion
This study and previous reports [13,14,26] demonstrates
that myostatin mRNA and protein are expressed in cardio-
myocytes. However, its physiological role in cardiac muscle
growth remains unclear since myostatin null mice do not
display the profound alterations in cardiac muscle mass
evident in skeletal muscle [9]. Our study shows for the first
timethatmyostatinexpressionisregulateddevelopmentallyin
rat cardiomyocytes.E18foetalcardiomyocyteswereshownto
expresslowlevelsofmyostatinthatgraduallyincreased6-fold
in P10 rat cardiomyocytes. Given that the majority of rat
cardiomyocytes cease to proliferate shortly after birth [1–3],i t
was interesting to note that the increased expression of
myostatin coincided closely with the diminishing proliferative
index of neonatal rat cardiomyocytes with age. Hence, we
studied the effects of myostatin on cardiac proliferation and
observed that myostatin is a potent inhibitor of serum-induced
embryonic and neonatal cardiomyocyte proliferation. Taken
together, these observations support a developmental role for
myostatin in limiting cardiomyocyte proliferation.
Using FACS analysis, we have shown that myostatin
inhibits cardiac proliferation in vitro through a block in the
Fig. 5. Effects of myostatin on protein synthesis in proliferating and PE stimulated non-proliferating cardiomyocytes. The effect of myostatin on the rate of [
14C]-
phenylalanine incorporation in proliferating E18 cardiomyocytes culture with or without myostatin for 24 h. Data expressed as (a) total [
14C]-phenylalanine
incorporation shows significant difference in myostatin treated cultures compared to controls. Data expressed as (b) the rate of phenylalanine incorporation per
cell shows comparable protein synthesis rate between myostatin-treated and control cultures. (c) In contrast the effect of myostatin on the rate of [
14C]-
phenylalanine incorporation per cell in non-proliferating serum starved P2 cardiomyocytes following PE stimulation are significantly different to PE stimulated
controls. Data are means±SD from triplicate experiments. ⁎ indicates pb0.05.
Fig. 6. Myostatin stimulates SMAD2 phosphorylation in E18 cardiomyo-
cytes. (a) Representative western blot demonstrates myostatin's ability to
induce SMAD2 phosphorylation in proliferating E18 cardiomyocytes within
30 mins of treatment. E18 cardiomyocytes stimulated with 500 ng of
recombinant myostatin (R&D Systems) for the length of time indicated were
analysed by Western blotting for SMAD phosphorylation.
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 G1 to S phase cell cycle transition. Progression through the
G1-S phase transition is controlled by the activity of the G1-
acting cyclin:cyclin-dependent kinase (CDK) complex,
cyclin E:CDK2 [27]. CDK2-associated activity plays a key
role in regulating entry into and exit from S-phase of the cell
cycle. For instance, it has been demonstrated that microin-
jection of affinity-purified anti-cdk2 antibodies during G1,
inhibited entry into S phase [28]. Therefore, limiting CDK2
availability ultimately can lead to a G1 to S cell cycle arrest.
Accordingly, we observed that a decrease in CDK2 ex-
pression is part of the mechanism through which myostatin
acts to inhibit cardiomyocyte proliferation.
The CDK inhibitor p21 has been shown to inhibit cyclin:
CDK complexes, including those that promote cell cycle
progression through the G1 and S phase [29]. Furthermore,
overexpression of p21 has been shown to arrest cells in G1
[30]. Since p21 mRNA and protein is upregulated in
myostatin-treated E18 cardiomyocytes, our results suggests
that upregulation of p21 is also part of the mechanism
through which myostatin elicits a G1/S cell cycle block in
cardiomyocytes. Myostatin-mediated inhibition of skeletal
muscle myoblast proliferation has also been shown to
involve increased expression of p21, decreased CDK2
activity and protein expression that ultimately results in a
G1/S cell cycle arrest [24]. These observations highlight
similarities in cell cycle regulation by myostatin in both
skeletal muscle and cardiac myocytes.
In this study we observe that in proliferating cardiomyo-
cytes, myostatin induced SMAD2 phosphorylation within
30 min of stimulation and subsequently inhibited cardio-
myocyte cell division. It is noteworthy that TGF-β, which
also signals via the classical SMAD2/3 pathway, has been
reported to inhibit proliferation of immature cardiomyocytes
[31]. The anti-proliferative effect of myostatin and other
TGF-β family members, in conjunction with SMAD
signalling, is well recognised in other cell types [15,16,32].
SMAD phosphorylation following binding of these ligands
to their respective serine threonine kinase transmembrane
receptor leads to the formation of heteromeric complexes
with SMAD4. The complex then translocates into the
nucleus to bind promoter regions of target genes or interact
with various transcription factors to regulate gene expression
[33–35]. SMAD2 proteins are able to interact with a diverse
range of proteins that do not share a common motif [35,36].
Hence the phenotypic outcome following SMAD activation
i st h e r e f o r el i k e l yt od e p e n do nt h eS M A D - b i n d i n g
transcription factors present within the nucleus at the time
of their activation. We propose that SMAD2 activation in
myostatin treated E18 cardiomyocyte cultures most likely
affects proliferation, as very little hypertrophic growth is
evident at this age [1–3].
Our study also shows that in adult cardiomyocytes, where
adaptive growth occurs mainly by hypertrophy [1], myos-
tatin expression is maintained but at a much lower level.
Since the majority of adult cardiomyocytes have lost their
ability todivideandexpressverylowlevelsofkey molecules
involved in cell division, we propose that high levels of
myostatin, perhaps, are not necessary at this age to actively
inhibit cell proliferation. We speculate that the expression
of myostatin in adult cardiomyocytes might reflect a
potential role in modulating hypertrophic growth rather
than hyperplastic growth. Indeed, as observed for myostatin
[14], adenovirus-mediated expression of growth differenti-
ation factor 15 (GDF15), another member of the TGF-β
family, has been shown to antagonise agonist-induced
hypertrophy in P2 cardiomyocytes in vitro. Interestingly,
this was shown to involve SMAD2/3 activation [37].
Furthermore, overexpression of SMAD2 in serum-starved
cultured neonatal cardiomyocytes inhibits agonist-induced
cardiomyocyte hypertrophy in vitro [37]. Thus the ability
of myostatin to affect both hyperplastic and hypertrophic
growth, depending on the physiological status of the
cardiomyocyte, might be partly related to the transcriptional
pathways influenced following SMAD activation by
myostatin.
Myostatin knockout mice studies indicate that the cardiac
muscle in these mice is not as grossly enlarged as their
skeletal muscle [9,14]. This suggests that other regulators
can compensate for the absence of myostatin in cardiac
muscle. Nevertheless, relatively smaller cardiomyocytes are
observed in myostatin knockout mice compared to their
wildtype counterparts [14]. The observation that cardiac-
specific overexpression of CDK2 increases cardiomyocyte
proliferation and results in significantly smaller cardiomyo-
cytes [38], suggests that the relatively smaller cardiomyo-
cytes observed in myostatin knockout mice might be linked
to abnormal proliferation. Thus, it will be interesting to
determine whether the proliferative capacity of cardiomyo-
cytes obtained from myostatin knockout mice is enhanced. It
also is worth noting that satellite cells isolated from
myostatin knockout mice have an enhanced proliferation
rate [25] and that their cardiomyocytes display exuberant cell
enlargement in response to the hypertrophic agonist,
phenylepherine [14].
Our observations emphasise the fact that molecules that
regulate cell cycle gene expression play a critical role in the
proliferation of cardiomyocytes and that their identification
and manipulation might help to extend the proliferative
capacity of cardiomyocytes. A role for myostatin in
cardiomyocyte growth is further supported by several other
observations. Firstly, IGF-1 mediates stretch-induced upre-
gulation of myostatin in neonatal rat cardiomyocytes [26];
secondly, myostatin is induced in cells immediately
surrounding a myocardial infarct for up to 30 days post
infarct [13]; and finally, myostatin is upregulated dramati-
cally in the hearts of AKT knockout mice, a genetic model of
cardiac hypertrophy [14]. These observations, together with
those from our study, demonstrate that myostatin plays an
important role in modulating cardiac growth. The emerging
picture is that myostatin affects both hyperplastic and
hypertrophic growth in cardiomyocytes, depending on their
physiological and growth status.
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